Ascentage Pharma将Marina S. Bozilenko和Debra Yu博士加进其董事会,以促进增长和药物发展。 Ascentage Pharma adds Marina S. Bozilenko and Dr. Debra Yu to its board to enhance growth and drug development.

Ascentage Pharma是一家为癌症等未得到满足的医疗需求进行治疗的公司,它增加了Marina S. Bozilenko和Debra Yu博士作为独立董事参加董事会。 Ascentage Pharma, a company developing treatments for unmet medical needs like cancer, has added Marina S. Bozilenko and Dr. Debra Yu to its board as independent directors. 两者在生物制药业的金融、投资和战略管理方面都有丰富的经验。 Both have deep experience in finance, investment, and strategic management in biopharmaceuticals. 随着该公司扩大临床试验和开发新的疗法,包括抗药性白血病药物,预计他们的专业知识将有助于该公司的增长。 Their expertise is expected to help the company grow as it expands its clinical trials and develops new therapies, including a drug for drug-resistant leukemia.